About Prothena Corporation plc
https://www.prothena.comProthena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States.
CEO
Gene G. Kinney
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 76
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Chardan Capital
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
FMR LLC
Shares:7.9M
Value:$72.69M
BLACKROCK INC.
Shares:3.86M
Value:$35.49M
BLACKROCK, INC.
Shares:3.6M
Value:$33.11M
Summary
Showing Top 3 of 247
About Prothena Corporation plc
https://www.prothena.comProthena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.42M ▼ | $13.72M ▼ | $-36.54M ▲ | -1.51K% ▲ | $-0.68 ▲ | $-35.94M ▲ |
| Q2-2025 | $4.42M ▲ | $89.04M ▲ | $-125.77M ▼ | -2.85K% ▼ | $-2.34 ▼ | $-51.78M ▲ |
| Q1-2025 | $2.83M ▲ | $68.41M ▲ | $-60.2M ▼ | -2.13K% ▲ | $-1.12 ▼ | $-65.36M ▼ |
| Q4-2024 | $2.12M ▲ | $67.02M ▼ | $-57.96M ▲ | -2.73K% ▲ | $-1.08 ▲ | $-64.68M ▲ |
| Q3-2024 | $970K | $67.48M | $-59M | -6.08K% | $-1.1 | $-66.29M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $330.84M ▼ | $352.63M ▼ | $57.64M ▼ | $294.99M ▼ |
| Q2-2025 | $371.44M ▼ | $399.07M ▼ | $74.73M ▲ | $324.33M ▼ |
| Q1-2025 | $417.94M ▼ | $495.34M ▼ | $57.66M ▼ | $437.68M ▼ |
| Q4-2024 | $471.39M ▼ | $547.11M ▼ | $60.18M ▼ | $486.93M ▼ |
| Q3-2024 | $519.26M | $595.25M | $60.89M | $534.36M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-36.54M ▲ | $-40.56M ▲ | $-10K ▲ | $-17K ▲ | $-40.59M ▲ | $-40.58M ▲ |
| Q2-2025 | $-125.77M ▼ | $-46.34M ▲ | $-86K ▼ | $-74K ▼ | $-46.5M ▲ | $-46.43M ▲ |
| Q1-2025 | $-60.2M ▼ | $-53.36M ▼ | $-42K ▲ | $-48K ▲ | $-53.45M ▼ | $-53.41M ▼ |
| Q4-2024 | $-57.96M ▲ | $-47.77M ▼ | $-43K ▼ | $-59K ▼ | $-47.87M ▼ | $-47.81M ▼ |
| Q3-2024 | $-59M | $-45.19M | $-9K | $333K | $-44.86M | $-45.2M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaboration | $130.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 License | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Gene G. Kinney
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 76
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Chardan Capital
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
FMR LLC
Shares:7.9M
Value:$72.69M
BLACKROCK INC.
Shares:3.86M
Value:$35.49M
BLACKROCK, INC.
Shares:3.6M
Value:$33.11M
Summary
Showing Top 3 of 247